Dr. Reddy’s Laboratories (NSE: DRREDDY) Q2 2025 Earnings Call dated Nov. 05, 2024 Corporate Participants: Richa Periwal — Head of IR M. V. Narasimham — CFO Erez Israeli — CEO Analysts: Kunal Dhamesha — Analyst Neha Manpuria — Analyst Amey Chalke — Analyst Mikaela Franceschina — Analyst Harith Ahamed — Analyst Damayanti Kerai — Analyst […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) Q3 2025 Earnings Call dated Jan. 23, 2025 Corporate Participants: Richa Periwal — Head, Investor Relations & Corporate Analytics M V Narasimham — Chief Financial Officer Erez Israeli — Chief Executive Officer Analysts: Kunal Dhamesha — Analyst Neha Manpuria — Analyst Amey Chalke — Analyst Bino Pathiparampil — Analyst Surya […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) Q4 2025 Earnings Call dated May. 09, 2025 Corporate Participants: Richa Periwal — Head, Corporate Analytics, Corporate Strategy and Investor Relations M V Narasimham — Chief Financial Officer Erez Israeli — Chief Executive Officer Unidentified Speaker Analysts: Neha Manpuria — Analyst Kunal Dhamesha — Analyst Madhav Marda — Analyst Amey […]
Dr. Reddy’s Laboratories (NSE: DRREDDY) Q1 2026 Earnings Call dated Jul. 23, 2025 Corporate Participants: Aishwarya Sitharam — Investor Relations Richa Periwal — Head of Investor Relations M.V. Narasimham — Chief Financial Officer Erez Israeli — Chief Executive Officer Analysts: Amey Chalke — Analyst Neha Manpuria — Analyst Damayanti Kerai — Analyst Madhav Marda — […]
Company Overview: Dr. Reddy’s Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations. Financial Results: Dr. Reddy’s Laboratories reported Total revenue for Q4FY25 of ₹ 9,050 Crore up from ₹7,311 Crore in Q4FY24, a […]
Dr. Reddy’s Laboratories ( NSE : DRREDDY) Q2 FY24 Earnings Concall dated Oct. 27, 2023 Corporate Participants: Richa Periwal — Head Of Investor Relations Parag Agarwal — Chief Financial Officer Erez Israeli — Chief Executive Officer Analysts: Mikaela Franceschina — Barclays — Analyst Kunal Dhamesha — Macquarie — Analyst Neha Manpuria — Bank of America […]
Dr. Reddy’s Laboratories (NSE:DRREDDY) Q4 FY23 Earnings Concall dated May. 10, 2023. Corporate Participants: Richa Periwal — Investor Relations G V Prasad — Co-Chairman and Managing Director Parag Agarwal — Chief Financial Officer Erez Israeli — Chief Executive Officer Analysts: Mikhaila — Barclays — Analyst Surya Patra — PhillipCapital — Analyst Damayanti Kerai — HSBC — Analyst Neha Manpuria — Bank of America — Analyst Ankush Mahajan — Axis Securities — Analyst Kunal […]
Key highlights from Dr. Reddy’s Laboratories (DRREDDY) Q4 FY23 Earnings Concall Q&A Highlights: [00:21:55] Mikhaila at Barclays asked more details about the deal with Junshi, including the responsibilities of both parties and what convinced DRREDDY about their asset and its potential. Erez Israeli CEO said the company seeks unmet needs in India and collaborates with […]
“We are progressing well on our pipeline products. The number of filings in several of our key markets have been improving. The ANDA and DMF filings are expected to significantly improve during Q4. We are evaluating several inorganic opportunities across businesses in line with our strategy. We believe, all of these will lead to several […]
Dr. Reddy’s Laboratories Ltd. (NSE:DRREDDY) is a multinational pharmaceutical company based in Hyderabad, India. The company was founded in 1984 and has since grown to become a leading player in the global pharmaceutical industry. Dr. Reddy’s Laboratories specializes in the development, manufacturing, and marketing of generic drugs, active pharmaceutical ingredients (APIs), and proprietary products. The […]